Mizuho Securities analyst Uy Ear has maintained their bullish stance on ARQT stock, giving a Buy rating on February 26.
Uy Ear’s rating is based on the positive performance of Arcutis Biotherapeutics’ Zoryve franchise, which showed a notable rebound in prescriptions following a holiday-related dip. The total prescriptions (TRxs) for Zoryve increased by 7.0% week-over-week, while new prescriptions (NRxs) rose by 7.7%, indicating a strong recovery and surpassing expectations.
Furthermore, the Zoryve Cream 0.15% specifically demonstrated significant growth, with TRxs increasing by 11.2% and NRxs by 9.4% in the 31st week of its commercial availability. This consistent upward trend supports Uy Ear’s confidence in the stock, leading to a Buy rating as the sales trajectory aligns with and even exceeds the firm’s forecasts.
According to TipRanks, Ear is a 3-star analyst with an average return of 3.8% and a 40.61% success rate. Ear covers the Healthcare sector, focusing on stocks such as Arcutis Biotherapeutics, Revance Therapeutics, and Sarepta Therapeutics.
In another report released on February 26, Morgan Stanley also maintained a Buy rating on the stock with a $19.00 price target.